Navigation Links
Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research

cancer in the developing world will be presented in this presentation. -- Sunday, June 3, 2:00 PM - 6:00 PM, S Hall A2, Poster Number W2. About Eloxatin(R) Indications and Usage

Eloxatin(R) (oxaliplatin for injection), a DACH platinum, is approved in combination with infusional 5-FU/LV for the second-line treatment of patients with advanced carcinoma of the colon or rectum. In 2004, Eloxatin received additional approval for the first-line treatment of these patients. Based on data showing improvement in disease-free survival, Eloxatin was also approved in 2004 for use in combination with infusional 5-FU/LV in adjuvant (post- surgery) treatment of stage III colon cancer patients.

Clinical Safety Considerations

Eloxatin(R) should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents.

Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available.

Anaphylactic-like reactions to Eloxatin(R) have been reported and may occur within minutes of Eloxatin(R) administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms, and discontinuation of Eloxatin(R) therapy may be required.


    -- Eloxatin(R) should not be administered to patients with a history of

       known allergy to Eloxatin(R) or other platinum compounds.

       Hypersensitivity and anaphylactic/anaphylactoid reactions to

       Eloxatin(R) have been reported and were similar in nature and severity

       to those reported with other platinum compounds (ie, rash, urticaria,

       erythema, pruritus, and, rarely, bronchospasm and hypotension). These

       reactions occur within minutes of administration and should be managed

       with appropriate supportive therapy. Drug-related deaths from this

       reaction have been reported


    -- Eloxatin(R) may cause fet
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:5/22/2015)... N.C. , May 22, 2015  Research ... hosting its sixth Medical Affairs Roundtable ... (EDT) via a virtual roundtable to discuss "Medical ... Best Practices, Medical Affairs Consortium provides ... insights about the key challenges they face. The ...
(Date:5/22/2015)... The Taskforce representing Canada,s living victims ... that the Minister and Health Canada have put into this ... needs of the thalidomide survivors, and more than 70% of ... with annual adjustments for inflation. Certain of the ... based on the severity of their disability, tax free, with ...
(Date:5/22/2015)... , May 22, 2015  Amgen (NASDAQ: ... has commenced termination of its participation in ... AstraZeneca (LON:AZN, STO:AZN and NYSE: AZN ... in development for patients with moderate-to-severe plaque ... decision was based on events of suicidal ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... Corporation ( www.fluidnet.net ), an innovator of advanced intravenous ... Directors has unanimously appointed Benjamin E. Bulkley as President ... company,s Founder, Jeffrey Carlisle, who will serve as Fluidnet,s ... Board of Directors, Chuck Hadley, Chairman, said, "Fluidnet is ...
... Bulletin Board: IAGX ) announced today that based on ... of August that it expects its net sales for its second ... $2.8 to $3.2 million, an increase of 158% to 195% compared ... compared to the second quarter of the previous fiscal year. ...
Cached Medicine Technology:Fluidnet Corporation Appoints Benjamin E. Bulkley President and Chief Executive Officer 2Imagenetix, Inc. Provides Net Sales Guidance for the Second Quarter Fiscal 2011 2Imagenetix, Inc. Provides Net Sales Guidance for the Second Quarter Fiscal 2011 3
(Date:5/25/2015)... 2015 After the sensational buzz surrounding ... human wellness company Trivedi Master Wellness™ agrees ... world-class series titled, “Consciousness is Power.” Presently, the Live-Streaming ... 2015 at the routinely allotted time from 10:00pm PST/1:00pm ... be made available to the public and accessible on ...
(Date:5/24/2015)... The Rolling Stones Zip Code summer stadium ... Petco Park. This iconic group is ready for their ... had a warmup show in Los Angeles at the Henry ... this beloved band not only played their Sticky Fingers album ... "Jumping Jack Flash," "Moonlight Mile" and "All Down the ...
(Date:5/24/2015)... May 24, 2015 EnviroLeather™ by ... “InkGard™ Plus” – a classic, rugged leather grain ... allowing difficult stains, including ink, to be easily ... colors suitable for corporate, healthcare, hospitality and education ... with EnviroLeather’s goal of developing products that are ...
(Date:5/24/2015)... WI (PRWEB) May 24, 2015 ... Health System CEO - The ... and honored at the fourth annual ... April 15 at Geneva National in ... school): ,     -Badger High School,         Jonathan ...
(Date:5/23/2015)... 2015 With the implementation of the ... it increasingly difficult to provide their employees with a ... adequate insurance for employees stand to face strict penalties. ... integral part of a business’s success or failure. In ... Online USA Doctors has created a varying level of ...
Breaking Medicine News(10 mins):Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 2Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 3Health News:The Rolling Stones Tickets in San Diego, Orlando, Minneapolis, Dallas, Pittsburgh, Indianapolis, Atlanta, Detroit, Milwaukee, Kansas City, Columbus, Nashville & Raleigh 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3
... who are smokers and have a family history of brain aneurysm ... a brain aneurysm themselves. The research is published in the December ... of the American Academy of Neurology and will appear in the ... type of stroke, called subarachnoid hemorrhage, is one of the bleeding ...
... Priority in 2009SPRINGFIELD, Ill., Dec. 31 The following is ... Illinois:The economic situation is forcing more Illinois families to face ... of people are cutting back on necessities in order to ... it,s too expensive. High health care costs are leaving ...
... mcg/hr) Not Affected RARITAN, N.J., Dec. 31 PriCara(R), ... lot of 50 microgram/hour (mcg/hr) DURAGESIC(R) (fentanyl transdermal system) ... and one lot of 50 mcg/hr fentanyl patches sold ... voluntarily recalled as a precaution from wholesalers and pharmacies. ...
... XStor Medical Systems, a,privately held Silicon Valley ... advanced clinical applications and collaborative patient care.,The ... participating,hospitals, clinics, and healthcare systems to securely ... and patients. The,XStor Imaging Platform is a ...
... Watson Pharmaceuticals, Inc. (NYSE: WPI ), ... today announced that its subsidiary, Watson Laboratories, Inc., ... and Drug Administration to market its over-the-counter Nicotine ... 2 mg and 4 mg strengths.Nicotine Polacrilex Gum, ...
... deprivation therapy that prostate cancer patients often take gives them ... within a couple of years. Now, researchers at Johns Hopkins ... cancer cells in patients who no longer respond to this ... Cancer Research , could lead to a way to ...
Cached Medicine News:Health News:Smokers with stroke in the family 6 times more likely to have stroke too 2Health News:PriCara(R) Recalls 50 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches 2Health News:PriCara(R) Recalls 50 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches 3Health News:XStor Medical Systems Announces the Release of its Imaging Platform for Connectivity Between Healthcare Enterprises 2Health News:Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum 2Health News:Why prostate cancer patients fail hormone deprivation therapy 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: